Pharma is sitting on a multi-billion-pound opportunity and it’s buried in patient-reported data
Sciensus was proud to sponsor the Reuters Pharma 2025 event. In a keynote session, Vice President, Medical Affairs, Alastair MacDonald, explained why patient-reported data is a critical, but often-untapped asset for pharma.
Pharma currently sits on a goldmine of patient-reported data but the promise it offers for increasing profit is rarely optimised. By leveraging advanced analytics and in-person support, and forming meaningful partnerships with healthcare providers, pharma companies can and should maximise their return on investment and deliver measurable financial returns.
Our session at Pharma 2025 focused on how this direct engagement with patients, and how using hybrid patient support programs – which include both digital and in-person nursing support – foster improved adherence, actionable data, leading to better long-term patient clinical outcomes and value for Pharma.
The untapped value of real-world data
Pharma invests billions in R&D but some post-launch return on investment is lost, in part due to poor persistence and adherence. The figures look staggering at first, but we can overcome the opportunity gap. In 2024, the average cost for pharma to develop a new drug was $2.23 billion. (1) However, 70% (2) of pharma products that fall short of sales targets at launch continue doing so in subsequent years.
By implementing patient support programs (PSPs) and collecting real-world data (RWD) we can address this risk by supporting ongoing adherence and maximising ongoing commercial success.
Why hybrid PSPs are key to pharma’s success
Our extensive experience at Sciensus with our own case studies plus wider research tells us that hybrid patient support programs (PSPs) that combine both face-to-face and digital components drive increased patient acquisition and retention whilst generating meaningful and actionable data.
Well-designed hybrid PSPs include built-in mechanisms to drive adherence and manage side effects – improving patient experience – and digital tools such as apps, wearables, ePROs that capture rich patient insights to support ongoing development. Combining this with in-person nursing support has also been shown to further drive adherence, persistence, and better health outcomes.
Unlock untapped revenue opportunities
If you’re not monetising your RWE strategy, you’re leaving millions on the table. Connect with our team to explore how our hybrid approach can help you turn real-world evidence into real-world profit.
About Sciensus
Sciensus, sitting at the intersection of patients and their medications, is uniquely positioned to draw on 30 years of patient interactions across Europe to generate this crucial insight.
Every day we’re trusted to engage directly with patients, both in person and through digital solutions, enabling us to gather real-time, high-quality patient-reported data. This forms the backbone of our real-world data services.
Read more on our RWD insights
Thought Leadership
The impact of real-world data in gaining access to the European orphan drugs market.
Blogs
Patient engagement: the golden ticket to drive effective treatments and commercial success
Patient engagement early and consistently throughout their treatment plan can provide pharmaceutical and biotech companies with invaluable insights into how…
Blogs
Real-world data and shaping the future of healthcare
Real-world data’s role in healthcare strategy and pharma decision-making Here are two of the key ways in which RWD can…